Business
Atara Biotherapeutics Appoints Biotech and Finance Industry Veteran Ron Renaud as Non-Executive Chair of the Board of Directors
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company
About this update from Atara Biotherapeutics, Inc.
[{"type":"text","content":" SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--\nAtara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced the appointment of biotech and finance industry veteran Ron Renaud as a director and non-executive chair of the board of directors.\n\n\n“We are honored to have Ron Renaud lead our board of directors as we advance our pipeline programs across various stages of development and deliver on key corporate milestones,” said Pascal Touchon, president and chief executive officer of Atara Biotherapeutics. “The board and I are enthusiastic about Ron’s extensive experience, from both the Wall Street and corporate side, in strategic and corporate development, partnering, financing, board and executive leadership, as well as his strong industry relationships.”\n\n\nRon has served as Translate Bio’s chief executive officer since 2014. Formerly, Ron was at Idenix Pharmaceuticals, an innovative company in the field of viral human diseases where he served as chief financial officer, chief business officer and finally, president and chief executive officer. Under his leadership, Idenix refocused its drug-discovery and development efforts and streamlined operations prior to the Merck acquisition for approximately $3.85 billion in August 2014. Prior to joining Idenix, Ron served as executive vice president and chief financial officer of Keryx Biopharmaceuticals. Before joining Keryx, Ron was a biotechnology equity research analyst at J.P. Morgan, Schwab Soundview and Bear Stearns. He also spent more than five years at Amgen, where he held positions in clinical research, investor relations and finance. He serves on the board of directors of Translate Bio, Ikena Oncology and Axial Biotherapeutics.\n\n\n“I am very impressed with Atara’s pipeline, technologies and manufacturing platform, and by the quality of the leadership team,” said Ron Renaud. “It is an honor to join such an experienced board and I look forward to helping Atara create significant value for patients and our stockholders.”\n\n\nAbout Atara Biotherapeutics, Inc.\n\n\nAtara Biotherapeutics, Inc. (@Atarabio) is a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, auto...